By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the ...

Novavax (NVAX) has become a focus for investors after signing a license agreement that allows Pfizer to use its Matrix-M ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

If you are wondering whether Novavax (Nasdaq: NVAX) is priced attractively or already reflects its story, you are not alone. The stock last closed at US$9.75, with returns of 21.7% over 7 days, 40.5% ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

Shares rose 6.6% Monday on new partnership strategy outlined at J.P. Morgan conference. Sanofi deal and cost cuts drive ...

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for ...

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the ...